<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280615</url>
  </required_header>
  <id_info>
    <org_study_id>Omegarenal</org_study_id>
    <nct_id>NCT03280615</nct_id>
  </id_info>
  <brief_title>Omega 3 Fatty Acids in Patients With Chronic Renal Disease</brief_title>
  <official_title>Effects of the Supplementation With Omega 3 Fatty Acids in Patients With Chronic Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servicio de Salud Metropolitano Oriente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the tolerance and efficacy of an omega 3 fatty acids supplement on renal and
      vascular function and inflammatory parameters in patients with chronic renal disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a double blind trial in patients with chronic renal disease, the effects of a 3.7 g
      supplement of docosahexanoic and eicosapentanoic acids or a supplement of a similar dose of
      corn oil during 12 weeks, will be assessed on the following parameters:

        1. Urine albumin excretion

        2. Renal function measured with serum creatinine, cystatin C and beta-2 microglobulin

        3. Carotid intima media thickness and pulse wave velocity

        4. Inflammation status assessed measuring serum levels of C reactive protein and
           interleukin 6

        5. Metabolic control of diabetes

        6. Serum lipid levels
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly selected to receive 3.7 g of a supplement containing docosahexanoic and eicosapentanoic acids or a supplement containing corn oil. The supplements will be provided for 12 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Identical sachets containind the study supplement or corn oil will be number coded and provided to participants</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urine albumin excretion at 12 weeks of intervention</measure>
    <time_frame>At baseline and 12 weeks of intervention</time_frame>
    <description>Measurement of albumin excretion in a 24 hour urine sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in C reactive protein levels at 12 weeks of intervention</measure>
    <time_frame>At baseline and 12 weeks of intervention</time_frame>
    <description>Measurement of c reactive protein in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse wave velocity at 12 weeks of intervention</measure>
    <time_frame>At baseline and 12 weeks of intervention</time_frame>
    <description>Measurement of pulse wave velocity using a oscillometric device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Omega 3 fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corn oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Supplementation of 3.7 g of corn oil per day during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 fatty acids</intervention_name>
    <description>Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids</description>
    <arm_group_label>Omega 3 fatty acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Corn oil</intervention_name>
    <description>Corn oil will be the placebo comparator for omega 3 fatty acids supplement</description>
    <arm_group_label>Corn oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Urinary albumin excretion over 30 mg/g creatinin

          -  Chronic renal failure stage 2 to 4

          -  Absence of serious conditions such as cáncer, decompensated heart failure, chronic
             infections and severe arterial lesions

        Exclusion Criteria:

          -  Blood glucose levels over 180 mg/dl or glycosilated hemoglobin over 8%

          -  Presence of cognitive impairment that does not allow to sigin a written informed
             consent

          -  Alcohol or illicit drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Veronica Cornejo, MSc</last_name>
    <phone>+56229781411</phone>
    <email>vcornejo@inta.uchile.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Maria Pino, MSc</last_name>
    <phone>+56221897814</phone>
    <email>ampino@inta.uchile.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Nutrition and Food Technology University of Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Cornejo, MSc</last_name>
      <phone>+56229781411</phone>
      <email>vcornejo@inta.uchile.cl</email>
    </contact>
    <contact_backup>
      <last_name>Patricio Peirano, MD</last_name>
      <phone>+562291781411</phone>
      <email>ppeirano@inta.uchile.cl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Shapiro H, Theilla M, Attal-Singer J, Singer P. Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat Rev Nephrol. 2011 Feb;7(2):110-21. doi: 10.1038/nrneph.2010.156. Epub 2010 Dec 7. Review.</citation>
    <PMID>21135888</PMID>
  </reference>
  <reference>
    <citation>Borg M, Svensson M, Povlsen JV, Schmidt EB, Aalkjær C, Christensen JH, Ivarsen P. Long chain n-3 polyunsaturated fatty acids and vascular function in patients with chronic kidney disease and healthy subjects: a cross-sectional and comparative study. BMC Nephrol. 2016 Nov 21;17(1):184.</citation>
    <PMID>27871238</PMID>
  </reference>
  <reference>
    <citation>Xu T, Sun Y, Sun W, Yao L, Sun L, Liu L, Ma J, Wang L. Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis. Sci Rep. 2016 Dec 23;6:39346. doi: 10.1038/srep39346.</citation>
    <PMID>28008943</PMID>
  </reference>
  <reference>
    <citation>Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, Giltay EJ. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1676-83. doi: 10.2215/CJN.10441013. Epub 2014 Aug 7.</citation>
    <PMID>25104273</PMID>
  </reference>
  <reference>
    <citation>Malhotra R, Cavanaugh KL, Blot WJ, Ikizler TA, Lipworth L, Kabagambe EK. Dietary polyunsaturated fatty acids and incidence of end-stage renal disease in the Southern Community Cohort Study. BMC Nephrol. 2016 Oct 18;17(1):152.</citation>
    <PMID>27756237</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chile</investigator_affiliation>
    <investigator_full_name>Daniel Bunout</investigator_full_name>
    <investigator_title>Full profesor</investigator_title>
  </responsible_party>
  <keyword>Albuminuria</keyword>
  <keyword>Carotid Intima-Media Thickness</keyword>
  <keyword>Pulse Wave Velocity</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Sharing of information must be discussed with the sponsor</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

